Safety and Effectiveness of U-500 Insulin Therapy in Patients with Insulin-Resistant Type 2 Diabetes Mellitus

被引:20
作者
Quinn, Suzanne L. [1 ,3 ]
Lansang, M. Cecilia [1 ,3 ]
Mina, Deanna [2 ]
机构
[1] Univ Florida, Malcom Randall Vet Adm Med Ctr, Div Endocrinol, Gainesville, FL 32608 USA
[2] Univ Florida, Malcom Randall Vet Adm Med Ctr, Dept Pharm, Gainesville, FL 32608 USA
[3] Univ Florida, Coll Med, Gainesville, FL 32608 USA
来源
PHARMACOTHERAPY | 2011年 / 31卷 / 07期
关键词
U-500; insulin; insulin resistance; type 2 diabetes mellitus; REGULAR INSULIN; CLINICAL-EXPERIENCE; EXPOSURE; OBESITY; PHARMACOKINETICS; PREVALENCE;
D O I
10.1592/phco.31.7.695
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objective. To assess the safety and effectiveness of highly concentrated U-500 regular insulin in patients with insulin-resistant type 2 diabetes mellitus who were switched from U-100 insulin. Design. Retrospective cohort study Setting. Outpatient diabetes management clinic. Patients. Twenty-one adults with poorly controlled type 2 diabetes and insulin resistance who were referred to the clinic between July 1, 2007, and June 30, 2008, and whose therapy was changed from large doses of U-100 insulin to U-500 insulin. Measurements and Main Results. Demographic and clinical data were collected through a computerized medical record system. Insulin resistance was defined as a requirement of more than 200 units/day of insulin and more than 100 units/injection. The primary outcome was the change in hemoglobin A(1C) (A1C) after switching from any type of U-100 insulin to stabilization with U-500 highly concentrated regular insulin. Secondary outcomes were the changes in number of daily insulin injections, daily insulin dose, and body weight. With use of U-500 insulin, patients were able to achieve an average reduction in A1C of 1.7% (p<0.001). The mean number of daily injections decreased from 4.3 with U-100 insulin to 2.7 after using U-500 insulin (p<0.001), but changes in body weight after the change in insulin were not statistically significant (279.8 vs 279.2 lbs, p=0.429). No patient discontinued U-500 insulin during the study, and none experienced hypoglycemia severe enough to require the assistance of another individual. Conclusion. In patients with insulin-resistant diabetes who have requirements of more than 200 units/day or 100 units/injection, use of U-500 regular insulin provided the same or better glucose control compared with U-100 insulin, with fewer daily injections and reduced injection volume. Although this drug represents an excellent treatment option, its safe use requires an experienced physician, a motivated and cooperative patient, and a dynamic diabetes management team.
引用
收藏
页码:695 / 702
页数:8
相关论文
共 38 条
[31]   Starting and advancing insulin for type 2 diabetes: Algorithms and individualized methods are both necessary [J].
Riddle, Matthew C. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (02) :372-374
[32]  
Runy LA, 2004, HOSP HEALTH NETWORK, V78, P63
[33]  
sanofi-aventis U.S, 2010, LANTUS INSULIN GLARG
[34]  
Teplan Vladimir, 2007, Med Pregl, V60 Suppl 2, P28
[35]   Antiretroviral Therapy Exposure and Insulin Resistance in the Women's Interagency HIV Study [J].
Tien, Phyllis C. ;
Schneider, Michael F. ;
Cole, Stephen R. ;
Levine, Alexandra M. ;
Cohen, Mardge ;
DeHovitz, Jack ;
Young, Mary ;
Justman, Jessica E. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 49 (04) :369-376
[36]  
U.S. Food and Drug Administration, 2008, POT SIGN SER RISKS N
[37]  
US Department of Veterans Affairs, VA DOD CLIN PRACT GU
[38]   Use of U-500 regular insulin in type 2 diabetes [J].
Wafa, Wafic S. ;
Khan, Mukhtar I. .
DIABETES CARE, 2006, 29 (09) :2175-2176